Technology
Health
Biotechnology

Alimera Sciences

$0.8699
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0019 (0.22%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ALIM and other stocks, options, ETFs, and crypto commission-free!

About

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. Read More The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

Employees
124
Headquarters
Alpharetta, Georgia
Founded
2003
Market Cap
61.74M
Price-Earnings Ratio
3.11
Dividend Yield
0.00
Average Volume
113.98K
High Today
$0.881
Low Today
$0.83
Open Price
$0.8776
Volume
91.48K
52 Week High
$1.21
52 Week Low
$0.7181

Collections

Technology
Health
Biotechnology
Research And Development
Biopharmaceutical
Pharmaceutical
US
North America

News

Yahoo FinanceMay 22

Alimera Sciences Announces Launch of Direct-to-Patient Marketing Campaign to Raise Awareness and Educate Consumers on Diabetic Macular Edema and ILUVIEN®

Pilot program to be initiated in four U.S. cities leveraging radio, print and social media channels, with potential for future expansion ILUVIEN’s CONTINUOUS MICRODOSING™ delivery enables patients diagnosed with diabetic macular edema (DME) to maintain vision longer with fewer intra-ocular injections ATLANTA, May 22, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal di...

0
Yahoo FinanceMay 14

Alimera Sciences to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019

ATLANTA, May 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that President and CEO, Rick Eiswirth will present a corporate overview and meet with investors at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019. Mr. Eiswirth’s presentation will be held at 2:00 PM PT in Room 9 of the Beverly Hilton Hotel, 9876 Wilshire Blvd. in Beverly Hills, Calif. Inve...

39
Seeking AlphaMay 4

Alimera Sciences, Inc. (ALIM) CEO Dan Myers on Q1 2019 Results - Earnings Call Transcript

81

Earnings

-$0.11
-$0.08
-$0.05
-$0.02
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 29, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.